European Atherosclerosis Journal,
Год журнала:
2024,
Номер
3(3), С. 67 - 72
Опубликована: Дек. 31, 2024
Background:
Lipoprotein(a)
[Lp(a)]
is
a
relatively
new
but
underutilized
biomarker
in
the
context
of
atherosclerotic
cardiovascular
disease
(ASCVD).
Objectives:
To
explore
clinical
implementation
Lp(a)
measurement
and
current
practices
hospital
specialised
settings
Italy.
Methods:
An
anonymous
online
questionnaire
was
distributed
to
Italian
physicians
examine
habits
clinicians
regarding
measurement.
The
survey
covered
three
topics:
1)
information
on
setting
physicians,
2)
questions
for
who
reported
not
measuring
Lp(a),
understand
reasons
requesting
test,
3)
measure
investigate
its
use
patient
management.
Results:
A
total
978
responses
were
received.
Overall,
63.1%
working
hospital;
12.2%
being
territorial
specialist.
Regular
by
32.1%
clinicians.
Among
those
do
main
barriers
include
high
cost
limited
availability
test.
threshold
value
defining
elevated
levels
varies
significantly
among
professionals,
with
36.7%
considering
above
30
mg/dL
be
32.7%
50
elevated.
Clinical
management
patients
primarily
includes
intensification
lipid-lowering
therapy
(69.2%),
risk
factors
(48.7%),
lifestyle
recommendations
(37.4%).
Conclusions:
highlights
heterogeneity
approach
managing
clinicians,
underscoring
importance
clear
guidelines
greater
accessibility
test
optimize
stratification
improve
outcomes.
Frontiers in Cardiovascular Medicine,
Год журнала:
2025,
Номер
12
Опубликована: Фев. 14, 2025
Background
Multiple
guidelines
recommend
detection
of
and
early
risk
factor
management
for
elevated
lipoprotein(a)
[Lp(a)].
Effective
implementation
requires
assessment
knowledge
practices
regarding
Lp(a)
among
medical
specialists.
Aim
To
assess
awareness,
the
treatment
specialist
physicians
in
Singapore.
Methods
Seventy-five
practicing
specialists
cardiology
(
n
=
33)
or
endocrinology
42)
anonymously
completed
a
structured
questionnaire
that
assessed
above
three
aims.
Results
The
majority
respondents
(83%)
rated
their
familiarity
with
as
at
least
average,
greater
percentage
endocrinologists
being
less
familiar
than
cardiologists
(29%
vs.
3%,
P
<
0.01).
57%
were
aware
one
guideline
consensus
statement
on
Lp(a),
which
was
more
frequent
(70%
48%,
0.05).
There
major
gaps
prevalence,
pathophysiological
role,
clinical
significance
correct
responses
30%;
44%
(33%
52%
endocrinologists)
never
tested
lack
effective
most
common
barrier
(59%).
A
higher
proportion
did
not
test
low
compared
regularly
13%,
0.02).
Education
training
considered
useful
improving
care
patients
Lp(a).
Conclusion
Major
identified
are
required
to
overcome
initial
barriers
testing.
American Journal of Preventive Cardiology,
Год журнала:
2025,
Номер
21, С. 100945 - 100945
Опубликована: Фев. 14, 2025
Lipoprotein(a)
[Lp(a)]
is
a
genetically
inherited,
independent
risk
factor
for
cardiovascular
disease
(CVD),
affecting
approximately
20-25%
of
the
global
population.
Elevated
Lp(a)
levels
are
associated
with
2-3-fold
increased
myocardial
infarction
and
aortic
valve
stenosis,
comparable
to
seen
in
individuals
familial
hypercholesterolemia.
Despite
its
clinical
relevance,
integration
screening
into
routine
practice
has
been
limited
by
inconsistent
measurement
techniques
lack
targeted
treatments.
Recent
advancements,
including
improved
assays
development
potential
Lp(a)-lowering
therapies,
have
renewed
focus
on
importance
screening.
This
review
aims
clarify
role
health
examining
current
evidence
who
should
be
screened,
when
occur,
most
accurate
methods
measuring
Lp(a).
Key
recommendations
include
universal,
one-time
adults,
selective
high-risk
pediatric
patients,
special
considerations
conditions
such
as
hypercholesterolemia
chronic
kidney
disease.
Advances
assay
technology
now
allow
more
precise
measurement,
supporting
better
stratification.
Additionally,
emerging
therapies
that
specifically
target
elevated
could
lead
personalized
management
CVD
risk.
Our
findings
support
assessment,
highlighting
improve
early
detection
prevention
strategies
across
diverse
patient
populations.
